A new Phase 2 trial at Johns Hopkins testing the GLP-1 drug pegsebrenatide in progressive MS may finally explain why adults on diabetes medications for a decade show measurably slower brain shrinkage. The mechanism appears to run through neuroinflammation, vascular health, and brain insulin resistance. The post A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage in progressive MS, and it could finally answer a question diabetes researchers have been circling for years appeared first on Space Daily .
A Phase 2 trial just began testing whether a GLP-1 drug can slow brain shrinkage in progressive MS, and it could finally answer a question diabetes researchers have been circling for years
